ReviewCardiovascular and interventional radiology2022
TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC.
Review in Cardiovascular and interventional radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of the value of albumin-bilirubin grading on changes in liver function and its prognostic assessment in patients with hepatocellular carcinoma treated with transhepatic arterial chemoembolization.World journal of surgical oncology · 2025Pooled it
- Quantitative Comparison of Yettirium-90 (Y90) PET/CT and Y90 SPECT/CT Voxel-Based Dosimetry post Resin Y90 Microsphere Radioembolization.Cardiovascular and interventional radiology · 2026Article
- LaparoscopicAnnals of surgical treatment and research · 2026Article
- Role of MRI in Imaging Assessment of Radiation-Based Treatment of Hepatocellular Carcinoma.Cancers · 2026Review
- A review of established and new developments in local therapies for liver cancer.ESMO gastrointestinal oncology · 2026Review
- Liver enhancement using rapid kVp-switching dual-energy CT with reduced iodine contrast dose compared with single-energy CT with standard iodine dose: an intra-patient comparison.Abdominal radiology (New York) · 2026Article
- Biliary and respiratory complications after right hepatectomy for hepatocellular carcinoma following selective internal radiation therapy (SIRT): a retrospective case-control study.Hepatobiliary surgery and nutrition · 2025Article
- Long-term outcomes of Yttrium-90 transarterial radioembolization for patients with hepatocellular carcinoma.European journal of nuclear medicine and molecular imaging · 2025Article
- A fundamentally new direction in embolization using reactive chemistry in a swine model.Scientific reports · 2025Article
- TACE vs. TARE for HCC ≥ 8 cm: A propensity score analysis.Abdominal radiology (New York) · 2025Article
- Treatments and cancer: implications for radiologists.Frontiers in immunology · 2025Review
- The effect of interval time of transcatheter arterial chemoembolization with drug-eluting beads on the efficacy and safety of unresectable hepatocellular carcinoma: a case-control study.Frontiers in oncology · 2025Article
- Outcome of Transarterial Radioembolization in the Treatment of Hepatocellular Carcinoma: Glass Versus Resin Microsphere.Cardiovascular and interventional radiology · 2024Article
- Article
- The Deterioration of Sarcopenia Post-Transarterial Radioembolization with Holmium-166 Serves as a Predictor for Disease Progression at 3 Months in Patients with Advanced Hepatocellular Carcinoma: A Pilot Study.Journal of personalized medicine · 2024Article
- Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.Current oncology (Toronto, Ont.) · 2024Review
- Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm?Journal of liver cancer · 2024Article
- Development and verification of a nomogram for predicting portal vein tumor thrombosis in hepatocellular carcinoma.American journal of translational research · 2024Article
- Outcome of transarterial radioembolization in patients with hepatocellular carcinoma as a first-line interventional therapy and after a previous transarterial chemoembolization.Frontiers in radiology · 2024Article
- Applications of Yttrium-90 (OncoTargets and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Barcelona Clinic Liver Cancer (BCLC) system is the most commonly used staging system for hepatocellular carcinoma (HCC) in Western countries. BCLC aims to categorize patients into five stages with different prognoses and to allocate treatment according to these stages based on the best possible contemporary evidence. Transarterial radioembolization (TARE) has recently entered at the left of the BCLC algorithm (i.e., BCLC 0-A), mainly because of negative phase III trials in BCLC C stage. TARE has shown a steady increase in nationwide studies over the past 20 years and has even been adopted in some tertiary centers as the primary HCC treatment across all BCLC stages. We aimed to review the history of TARE in HCC, starting from advanced HCC and gradually expanding to earlier stages at the left of the BCLC system.
Indexed as
Identifiers
35149884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.